Gilead's Once Yearly Lenacapavir Formulations Show Sustained Efficacy for HIV PrEP in Phase 1 Study

Yeztugo vs Cabotegravir: Which Long-Acting PrEP Is Right for You?

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Antiretroviral Management of HIV: New Data From CROI 2025

FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention

Lenacapavir Checklist Video

ЭТО ОПАСНО ПРИ ВЫСОКОМ ХОЛЕСТЕРИНЕ? 5 опасных ошибок

Lenacapavir

Injectable HIV drug approved in the US - when will it be available in other countries? | DW News

Why We've Only Cured HIV Seven Times

Advancements in Long-Acting Drugs for HIV Treatment and Prevention, Including Emerging Therapies

Carl Schmid on Supreme Court Ruling Upholding ACA Preventive Coverage & Its Impact on HIV Prevention

Mini-Lecture Series: HIV Capsid Inhibitors: Mechanism of Action

HIV PrEP Talk Webinar: Navigating Policy, Progress, and Perspectives - SHLI

HIV Pre-Exposure Prophylaxis (PrEP): Lenacapavir

HIV breakthrough drug priced out of reach for those who need it most | DW News

My doctor's take on HIV long-lasting injectable ARV's

Gilead CEO On 2024 drug pipeline: Expect results from around two dozen clinical trials

Recording for LEN Gilead Webinar

Study finds Lenacapavir highly effective in preventing HIV

Can a twice-a-year shot help end the HIV/AIDS epidemic?